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Abstract
Background: Kabul has over 12,000 people who inject drugs (PWID), most of them heroin users, and opioid
substitution therapy has recently been introduced as an effective method to reduce opioid use. We aimed to
evaluate a pilot Opioid Substitution Therapy Pilot Program (OSTPP) in Kabul, Afghanistan, particularly to (1) describe
characteristics of the participants enrolled in the program and (2) identify factors associated with client retention in
the OSTPP.
Findings: Two cross-sectional surveys evaluated participants attending the OSTPP at baseline (n = 83) and 18
months after (n = 57). Questionnaires assessed socio-demographic, drug use behavior, and general and mental
health factors. After 18 months, 57 participants remained in the OSTPP. Participants lost to follow-up were younger
(p < 0.01) and married (p < 0.01) and had no family contact (p < 0.01). Participants at 18 months reported no
criminal activity in the last month and only two (3.5 %) reported heroin use in the last month, constituting
significant decreases from baseline.
Conclusions: While preliminary results are promising, further evaluation is needed to determine the feasibility of
implementing OSTPP in this setting and effectiveness in reducing injection risk behaviors in Afghanistan.
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Introduction
In 2012, it was estimated that over 12,000 PWID were
living in Kabul alone [1]. Between 2008 and 2011,
Afghanistan was one of only five countries in the world
to report an increase in the prevalence of injecting drug
use [2], likely attributable to broad structural factors in-
cluding poor socioeconomic conditions, the increasing
number of returning refugees, high-opium production,
and new trafficking routes [3, 4]. As elsewhere, in
Afghanistan, injecting drug use has been associated with
hepatitis C virus (HCV) and HIV transmission [5, 6] and
with substantial social implications, such as loss of em-
ployment and productivity [7].
Opioid substitution therapy (OST) is an evidence-based
pharmacological intervention to treat opioid dependence
[8]. OST replaces the use of illicit opiates, indirectly re-
duces injecting frequency, and improves health and social
outcomes and evidence further suggests that OST may re-
duce HIV incidence [9, 10].
In February 2010, Medecins du Monde (MdM), with
support from the Afghan Ministry of Public Health
(MoPH) and the World Bank, implemented the first
OST pilot program (OSTPP) in Kabul, Afghanistan. In
2012, the Johns Hopkins University (JHU) evaluated the
OSTPP in collaboration with MdM and the Afghan
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National AIDS Control Program (NACP). This analysis
aimed to (1) describe the characteristics of the partici-
pants enrolled in the program and (2) identify factors as-
sociated with client retention.
Methods
Setting and participants
The OSTPP clinic was located in central Kabul. Daily
clinical visits were required of participants for daily
methadone dosing. Ancillary services included psycho-
social therapy, basic medical services, recreational activ-
ities, and educational programs. MdM enrolled active
injecting drug users giving priority to those with poorer
medical assessments. Participants were invited by MdM’s
out-reach services to enroll into the OSTPP. Edibility
criteria for baseline included providing consent and cur-
rently injecting heroin and for endline assessment in-
cluded being an enrolled participant of the OSTPP,
male, ≥18 years, and providing verbal informed consent.
Data collection and procedures
Data are derived from two cross-sectional surveys con-
ducted at enrollment (baseline) and at endline, 18 months
later. After completing the verbal informed consent
process, participants at baseline assessment and endline
were surveyed using a structured, interviewer-administered
questionnaire that included socio-demographic character-
istics, injecting behaviors, criminal history, social integra-
tion, and general and mental health topics. Data were
collected by trained MdM interviewers at baseline and by
trained JHU interviewers at endline. All questions were
developed in English, translated into Dari, and back-
translated by a certified translator. No participation incen-
tive was provided.
The study was approved by the Institutional Review
Boards of the Afghan MoPH and Johns Hopkins Bloom-
berg School of Public Health.
Measures
Mental health was assessed prior to enrollment by
self-report of depressive symptoms using a 10-item
measure developed by MdM for patient intake, which
included psychotic symptoms (five items) and post-
traumatic stress disorder (PTSD) symptoms (five
items). Responses to each symptom domain were
recorded as “Yes” (present) or “No” (absent) and
added to obtain total symptom counts and for each
domain, separately. Cronbach’s alpha was 0.93. Gen-
eral health status was self-reported using a 10-point
Likert scale, with higher scores indicating better self-
reported health.
Measures of substance use behaviors included heroin
use after enrollment into the OSTPP, frequency of in-
jection in the last month (once a day/daily vs. less than
daily for analysis), history of imprisonment, and fre-
quency of contact with family members in the past
month and were categorized as binary responses. HIV
1/2 and HCV-Ab testing were conducted by MDM
using Afghan MoPH guidelines.
Data analysis
Secondary data analysis was conducted with data from
baseline participants and endline participants. MdM col-
lects participant’s data anonymously, prohibiting identifi-
cation of the participants who were later enrolled into
Fig. 1 Participants enrolled and surveyed in the OSTPP between February 2010 and May 2012. Eighty-three participants were initially enrolled
and surveyed by MdM, 38 dropped-out, and 45 were retained. After 18 months, 57 clients were surveyed by JHU
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the program. Descriptive statistics summarized socio-
demographic characteristics, health status, heroin use,
and injecting characteristics. Attrition analysis was con-
ducted to compare participant characteristics of those
who remained enrolled in the program and those lost to
follow-up. Statistical comparisons were made using
chi-square tests for binary and categorical data and in-
dependent t-tests for continuous variables. STATA
version 12 (College Station, TX 2012) was used for
statistical analyses.
Table 1 Baseline socio-demographic and drug use characteristics of participants enrolled, lost to follow-up, and retained in the
OSTPP in Kabul, Afghanistan




Baseline participants retained by endline
(N = 45)
p value
n (%) n (%) n (%)
Age (years)
18–24 13 (15.7) 11 (29.0) 2 (4.4) <0.01
25–29 23 (27.7) 10 (26.3) 13 (28.9) 0.77
30–34 17 (20.5) 7 (18.4) 10 (22.2) 0.51
35+ 30 (36.1) 10 (26.3) 20 (44.4) 0.01
Marital statusa
Single 43(51.8) 14 (37.8) 29 (64.4) <0.01
Married/engaged 37 (44.5) 21 (56.8) 16 (35.6)
Family contact in the past month
No contact 21 (25.3) 16 (42.1) 5 (11.1) <0.01
Less than daily 16 (19.3) 7 (18.4) 9 (20.0)
Daily 46 (55.4) 15 (39.5) 31 (68.9)
General health score mean (SD) (range: 1–10) 5.1 (2.1) 5.2 (2.4) 5.0 (1.8) 0.67
Mental health symptoms (range: 1–20)
Total number of symptoms, mean (SD) 6.5 (3.7) 6.7 (4.4) 6.2 (2.9) 0.62
Depressive symptoms mean(SD) 4.3 (2.4) 4.5 (2.5) 4.1 (2.3) 0.42
PTSD symptoms mean (SD) 2.7 (1.6) 1.2 (1.5) 1.5 (1.6) 0.34
Psychotic symptoms mean (SD) 1.5 (1.4) 1.3 (1.7) 0.38 (1.1) <0.01
Frequency of heroin useb
Once a week—less than daily 1 (1.2) 1 (2.6) 0 (0) 0.05
Daily 79 (95.2) 36 (94.7) 43 (95.6)
No response 3 (3.6) 1 (2.6) 2 (4.4)
Ever injected drugs
Yes (not in the past month) 34 (41.0) 15 (39.5) 19 (42.2) 0.67
Yes (past month) 36 (43.4) 15 (38.5) 21 (46.7)
No response 13 (15.7) 8 (2.2) 5 (2.2)
Age first heroin use mean (SD) 22.8 (5.8) 21.1 (5.3) 24.4 (6.3) 0.01
Ever treated for substance use
Yes 62 (74.7) 29 (76.3) 33 (73.3) 0.42
No 19 (22.9) 9 (23.7) 10 (22.2)
No response 2 (2.4) 0 (0) 2 (4.4)
Ever in prison 43 (51.8) 21 (55.3) 22 (48.9) 0.43
HIV positivec 5 (6.0) 2 (5.2) 3 (6.6) 0.59
HCV positivec 50 (60.2) 22 (57.9) 28 (62.2) 0.59
aOne client refused to answer
bHeroine use includes injection, eating, sniffing, or smoking heroin
cHIV and HCV testing were conducted by MdM during completion of the baseline questionnaire
dProportion presented in this table may not add to 100 % due to rounding
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Findings
Overall, between February 2010 and May 2012, 95 partici-
pants were enrolled in the OSTPP. The initial number of
program participants was restricted by NACP and the
Ministry of Counter Narcotics to 71 participants, who
were enrolled between February and September 2010. An
additional 12 participants were enrolled between October
2011 and Nov 2011, totaling 83 participants with a base-
line evaluation. An additional 12 participants were en-
rolled between November 2011 and May 2012, resulting
in a total of 57 clients who were surveyed at endline by
JHU (Fig. 1). All participants were male and with a mean
age of 32.2 years (SD = 7.8) at baseline. The mean daily
methadone dose was of 131 mg/day to all participants
(range = 30–270 mg/day). Of the 83 clients who were ini-
tially enrolled and surveyed by MdM, 38 clients were lost
to follow-up (45.7 %) and 45 clients were retained (54.2)
and at 18 months (Table 1).
Reasons for loss to follow-up included voluntary with-
drawal (n = 9, 20 %), imprisonment (n = 8, 17.8 %), death
(n = 5, 11.1 %), migration (n = 3, 6.7 %), and other causes
(n = 20, 44.4 %). Relative to those lost to follow-up, par-
ticipants who remained enrolled were more likely to be
older (p = 0.01), single (p < 0.01), report daily family con-
tact in the past month (p < 0.01), older age at first heroin
use (p = 0.01), and fewer number of psychotic symptoms
(p < 0.01) (Tables 1 and 2).
Relative to baseline participants, endline participants
had better mental health (p < 0.001) and general health
scores (p < 0.001), reported less heroin use (p < 0.001),
less criminal activity (p < 0.001), improved family contact
(p < 0.001), and a source of income (p < 0.001) (see
Table 2).
Discussion
This is the first report on the retention, characteristics,
and behaviors of participants in the only OSTPP in
Kabul, Afghanistan. Results suggest that even under
challenging circumstances, participants who remained
active in the OSTPP reported improved general and
mental health status, decreased heroin use and criminal
activity, and improved family contact.
Program retention was relatively high (over 50 %) and
comparable to programs in high-income countries, des-
pite severe disruptions in methadone provision derived
from a non-functioning importation policy during the
OSTPP implementation [11]. This disruption occurred
between April and May 2011 and has been associated
with the death of 4 clients [4, 12]. This suggests that
even in conditions of substantial challenges, including
restricted clinic working hours, required daily treatment
visits, methadone stock-outs, and general instability and
physical danger in Kabul, scale-up of methadone-based
OST may be feasible in Kabul and could promote a posi-
tive change in specific behaviors and characteristics of
participants on treatment.
Several baseline factors associated with loss to follow-
up and retention were identified. Age at enrollment
was related to retention; participants lost to follow-up
were younger than those who remained enrolled. Loss
of young participants is a critical barrier to overcome:
young people are more vulnerable to initiation of sub-
stance use and most new HIV infections are reported
among those 18–30 years old [13]. Understanding the
needs and social situation of young people will facilitate
OST development and implementation across this age
group and may mitigate their risk of HIV and HCV
infection [9].
Retention in the OSTPP was more likely among those
with more family contact, suggesting that participants
may benefit from family engagement in a treatment pro-
gram [14]. Contrary to expectations, single participants
at baseline were more likely to continue in the program,
which may reflect having fewer social and economic
needs than married participants and, thus, having more
freedom to attend the clinic on a daily basis. The
provision of take-home methadone, which has shown
promise in other OST programs may help improve pro-
gram retention by addressing the needs of participants
who are married or employed [15–18].
Table 2 Distribution of characteristics among participants at baseline and endline evaluation of an OSTPP, in Kabul, Afghanistan
Characteristics Baseline participants (N = 83) Endline participants (N = 57) p
valuen (%) n (%)
Mental health symptom median (SD) 6 (24.1) 3.0 (3.7) <0.001
General health symptom median (SD) 5.0 (2.1) 8.0 (1.7) <0.001
Current heroin use (any type) 83 (100) 35 (61.4)a <0.001
Correct HIV knowledge 50 (60.2) 43 (75.4) 0.07
Has source of income 17 (20.5) 48 (84.2) <0.001
History of criminal activity 51 (61.5) 0 (0) <0.001
Any family contact 21 (25.3) 41 (71.9) <0.001
aAt endline, 15 participants (26.3 %) reported injecting heroin at some point after enrollment. Two participants (3.5 %) reported injecting in the last month
bAll six characteristics presented in column one reflect the characteristic reported before enrollment vs. characteristic reported after enrollment
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The majority of participants retained in OSTPP re-
ported reductions in heroin use, which is comparable to
estimates reported in other countries [19]. By stopping
heroin use, reductions in needle sharing and injecting fre-
quency are expected, translating into fewer opportunities
for HIV and HCV transmission and acquisition [20, 21],
as well as other social benefits such as decreased criminal
activity [22]. However, for those who continue to use her-
oin but at a lower rate, the effect of OSTPP on HIV and
HCV infection might be marginal given the limited op-
tions and access to other harm reduction services [4, 23].
Findings should be viewed in light of several limita-
tions. Due to restrictions on the number of enrolled par-
ticipants, the overall evaluation’s sample size was small.
Almost half of the baseline participants were lost to
follow-up, decreasing the study’s power and directly af-
fecting the generalizability and our capacity to make in-
ferences. Participants in this study tended to be older,
single, report ever being in prison, and report lower
levels of employment than the wider population of
injecting drug users in Kabul, thus further limiting the
generalizability of our findings to the wider population
of PWID in the city [1]. Interpretation of the results that
compare the 83 baseline participants to the 57 endline
participants must consider the fact that 12 participants
did not provide baseline data. This may limit our cap-
acity to accurately understand the factors associated with
retention and OST outcomes. The OSTPP assessment
was carried out within an existing program, lacking a
control group and randomization. Baseline and endline
data analysis reflect group changes and not individual
change. Another potential bias was social desirability
bias that is inherent in all socio-behavioral studies, par-
ticularly those that address illegal behaviors. The mental
health questions used as part of the evaluation have not
been validated for use among PWID. Future research
should include validated mental health assessments that
can better characterize the mental health problems of
PWID. Reasons for recidivism should be identified with
the aim of improving the program’s performance in
maintaining heroin cessation. Finally, we have no infor-
mation on participants’ participation in ancillary ser-
vices. This information would inform on the impact of
these services on participants’ retention.
Conclusion
Despite limitations, findings suggest that OST in
Afghanistan may be feasible in Kabul and could have
positive impacts on participant behavior, supporting
recommendations for use in other urban centers, such
as Herat, where opioid use is prevalent [1]. This study
provides preliminary data for future research and trials
of optimal treatment and harm reduction programs for
this setting.
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